Hester Biosciences Limited (HESTERBIO.BO)
INR 2469.0
(1.32%)
INR 2469.0
(1.32%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.44 Billion INR | -10.86% |
| 2022 | 2.74 Billion INR | 20.15% |
| 2021 | 2.28 Billion INR | 107.4% |
| 2020 | 1.1 Billion INR | -12.6% |
| 2019 | 1.25 Billion INR | 40.09% |
| 2018 | 898.49 Million INR | 30.63% |
| 2017 | 687.8 Million INR | 3.88% |
| 2016 | 662.12 Million INR | 12.4% |
| 2015 | 589.06 Million INR | 13.56% |
| 2014 | 518.7 Million INR | 14.61% |
| 2013 | 452.57 Million INR | 51.89% |
| 2012 | 297.95 Million INR | 112.52% |
| 2011 | 140.2 Million INR | -34.25% |
| 2010 | 213.24 Million INR | 5.84% |
| 2009 | 201.48 Million INR | 7.37% |
| 2008 | 187.66 Million INR | -6.83% |
| 2007 | 201.42 Million INR | -9.91% |
| 2006 | 223.57 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.39 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 2.44 Billion INR | -10.86% |
| 2023 Q4 | 2.44 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 2.73 Billion INR | 0.0% |
| 2022 Q2 | 2.67 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.74 Billion INR | 0.0% |
| 2022 FY | 2.74 Billion INR | 20.15% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 2.28 Billion INR | 107.4% |
| 2021 Q2 | 1.12 Billion INR | 0.0% |
| 2021 Q4 | 2.28 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.26 Billion INR | 0.0% |
| 2020 Q4 | 1.1 Billion INR | 0.0% |
| 2020 FY | 1.1 Billion INR | -12.6% |
| 2019 FY | 1.25 Billion INR | 40.09% |
| 2019 Q4 | 1.25 Billion INR | 0.0% |
| 2019 Q2 | 947.66 Million INR | 0.0% |
| 2018 FY | 898.49 Million INR | 30.63% |
| 2018 Q4 | 898.49 Million INR | 0.0% |
| 2017 FY | 687.8 Million INR | 3.88% |
| 2016 FY | 662.12 Million INR | 12.4% |
| 2015 FY | 589.06 Million INR | 13.56% |
| 2014 FY | 518.7 Million INR | 14.61% |
| 2013 FY | 452.57 Million INR | 51.89% |
| 2012 Q4 | 297.95 Million INR | 0.0% |
| 2012 FY | 297.95 Million INR | 112.52% |
| 2012 Q2 | 104.38 Million INR | 0.0% |
| 2011 FY | 140.2 Million INR | -34.25% |
| 2010 FY | 213.24 Million INR | 5.84% |
| 2009 FY | 201.48 Million INR | 7.37% |
| 2008 FY | 187.66 Million INR | -6.83% |
| 2007 FY | 201.42 Million INR | -9.91% |
| 2006 FY | 223.57 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | 352.8 Million INR | -592.681% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -14039.791% |
| Sigachi Industries Limited | 1.43 Billion INR | -70.832% |
| Bal Pharma Limited | 1.39 Billion INR | -74.995% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -1370.244% |
| Medico Remedies Limited | 80.5 Million INR | -2935.601% |
| Lasa Supergenerics Limited | 220.76 Million INR | -1006.975% |
| Venus Remedies Limited | 413.3 Million INR | -491.285% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -299.637% |
| Alpa Laboratories Limited | 52.46 Million INR | -4557.924% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 61.548% |
| Shilpa Medicare Limited | 9.37 Billion INR | 73.93% |
| Aarti Drugs Limited | 5.64 Billion INR | 56.691% |
| Lupin Limited | 29.21 Billion INR | 91.636% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 96.324% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 69.612% |
| Windlas Biotech Limited | 36.41 Million INR | -6611.837% |
| Suven Life Sciences Limited | 7.09 Million INR | -34333.986% |
| Eris Lifesciences Limited | 27.81 Billion INR | 91.213% |
| Valiant Laboratories Limited | 767.08 Million INR | -218.58% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 35.292% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 75.84% |
| Ipca Laboratories Limited | 14.38 Billion INR | 83.01% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -144.769% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 92.535% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 26.574% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Mankind Pharma Limited | 2.07 Billion INR | -17.959% |
| Laurus Labs Limited | 25.77 Billion INR | 90.518% |
| Piramal Pharma Limited | 47.1 Billion INR | 94.812% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -237.135% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 93.924% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 52.378% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 80.147% |
| Unichem Laboratories Limited | 2.47 Billion INR | 1.267% |
| Sequent Scientific Limited | 4.87 Billion INR | 49.891% |
| Novartis India Limited | 69.7 Million INR | -3406.141% |
| Wanbury Limited | 1.16 Billion INR | -109.794% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -275.987% |
| Wockhardt Limited | 23.56 Billion INR | 89.627% |
| Themis Medicare Limited | 957.92 Million INR | -155.113% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -2633.229% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 93.33% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -1325.111% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 87.793% |
| Divi's Laboratories Limited | 30 Million INR | -8045.933% |
| NATCO Pharma Limited | 3.71 Billion INR | 34.165% |
| Gufic Biosciences Limited | 3.32 Billion INR | 26.595% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -645.965% |
| Ind-Swift Limited | 10.13 Billion INR | 75.9% |
| Procter & Gamble Health Limited | 95.6 Million INR | -2456.255% |
| FDC Limited | 205.18 Million INR | -1091.013% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -26.34% |
| Granules India Limited | 13.15 Billion INR | 81.417% |
| Medicamen Biotech Limited | 308.17 Million INR | -692.992% |
| Alkem Laboratories Limited | 14.18 Billion INR | 82.771% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -5214.645% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -55579.654% |
| Brooks Laboratories Limited | 56.41 Million INR | -4231.484% |
| Megasoft Limited | 1.47 Billion INR | -66.19% |
| ZIM Laboratories Limited | 1.08 Billion INR | -124.562% |
| Strides Pharma Science Limited | 25.16 Billion INR | 90.29% |
| Neuland Laboratories Limited | 953.89 Million INR | -156.189% |
| Morepen Laboratories Limited | 289.99 Million INR | -742.706% |
| Hikal Limited | 8.17 Billion INR | 70.11% |
| Indoco Remedies Limited | 6.71 Billion INR | 63.632% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 14.328% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -672.212% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -148.118% |